ClinicalTrials.gg
CompletedNCT03458130Updated Nov 16, 2022Results posted

Study of AG10 in Amyloid Cardiomyopathy

A Phase 2 interventional study of AG10 and Placebo Oral Tablet in Familial ATTR-CM (ATTRm-CM, or FAC) and Wild-type ATTR-CM (ATTRwt-CM), sponsored by Eidos Therapeutics, a BridgeBio company. Completed at 13 sites in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-11-16.

Sponsored by Eidos Therapeutics, a BridgeBio company (part of BridgeBio) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

This prospective, randomized, multicenter, double-blind, parallel group, placebo-controlled, dose-ranging study will evaluate the safety, tolerability, PK (Pharmacokinetic) and PD (Pharmacodynamic) of AG10 compared to placebo administered on a background of stable heart failure therapy. Screening and randomization will be followed by a 28-day blinded, placebo-controlled treatment period.

Read the detailed description

A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients with Symptomatic Transthyretin Amyloid Cardiomyopathy.

The primary objective of this study is to evaluate the safety and tolerability of AG10 administered to adult patients with symptomatic transthyretin amyloid cardiomyopathy (ATTRCM).

This study will be a Phase 2, randomized, placebo-controlled, dose-ranging study in 45 male and/or female patients with symptomatic ATTR-CM aged 18 through 90 years.

If all doses are well tolerated, the duration of each patient's participation in the study will be 28 days of treatment. In addition, there will be a 28-day screening period before treatment and a 30-day follow-up period before the final Follow-up Visit.

This prospective, randomized, multicenter, double-blind, parallel group, placebo-controlled, dose-ranging study will evaluate the safety, tolerability, PK and PD of AG10 compared to placebo administered on a background of stable heart failure therapy. Screening and randomization will be followed by a 28-day blinded, placebo-controlled treatment period. secondary objectives of this study are: to characterize the pharmacokinetics (PK) of AG10 administered orally twice daily in patients with symptomatic ATTRCM, and to describe the pharmacodynamic (PD) properties of AG10 as assessed by established assays of transthyretin (TTR) stabilization, including Fluorescent Probe Exclusion (FPE) assay and Western blot, and to describe the Pharmacokinetic Pharmacodynamic (PKPD) relationship of AG10 in adult patients with symptomatic ATTRCM.

Eligible patients will be randomized in a 1:1:1 ratio to placebo or one of two different doses of AG10 administered twice daily. A minimum of 30% of patients enrolled will be mutant ATTR-CM.

02

Conditions studied

  • Familial ATTR-CM (ATTRm-CM, or FAC)
  • Wild-type ATTR-CM (ATTRwt-CM)
03

In context

Lead sponsor

Eidos Therapeutics, a BridgeBio company is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

First submitted after Eidos Therapeutics became part of BridgeBio.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have the ability to understand and sign a written form, which must be obtained prior to initiation of study procedures.
  2. Be a male or female ≥18 to ≤90 years of age.
  3. Have an established diagnosis of ATTR-CM with either wild-type transthyretin or a variant transthyretin genotype (assessed by genotyping, with patients with concurrent monoclonal gammopathy of undetermined significance requiring a confirmatory test using mass spectrometry) as defined by either positive endomyocardial or positive technetium pyrophosphate scan.
  4. Have a history of heart failure evidenced by at least one prior hospitalization for heart failure or clinical evidence of heart failure (without hospitalization) requiring medical management.
  5. Have (NYHA) Class II-III symptoms.
  6. Male patients and female patients of who engage in heterosexual intercourse must agree to use appropriate method(s) of .
  7. For patients taking cardiovascular medical therapy, with the exception of diuretic dosing, must be on stable doses (defined as no greater than 50% dose adjustment and no categorical changes of medications) for at least 2 weeks prior to Screening.

Exclusion criteria

Exclusion Criteria:

  1. Acute myocardial infarction, acute coronary syndrome or coronary revascularization within 90 days prior to Screening.
  2. Experienced stroke within 90 days prior to Screening.
  3. Has hemodynamic instability at Screening or Randomization that, in the judgment of the Principal Investigator (PI), would pose too great a risk for participation in the study.
  4. Has estimated (GFR) \<30 mL/min/1.73 m2 at Screening.
  5. Is likely to undergo heart transplantation within the next year.
  6. Has confirmed diagnosis of light-chain amyloidosis.
  7. Has abnormal liver function tests at Screening, defined as (ALT) or Aspartate Aminotransferase (AST) >3 × (ULN) or total >2 × ULN.
  8. Has abnormalities in clinical laboratory tests at Screening or Randomization that, in the judgment of the PI, would pose too great a risk for participation in the study.
  9. Known to study drug (AG10 or placebo), its metabolites, or formulation
  10. Current treatment with diflunisal, tafamidis, green tea, doxycycline, tauroursodeoxycholic acid (TUDCA)/Ursodiol, Patisiran or Inotersen within 14 days or 5 half-lives of the prior agent (whichever is longer) prior to Screening.
  11. Females who are pregnant or breastfeeding. Lactating females must agree to discontinue nursing before the study drug is administered. A negative serum pregnancy test at Screening and a negative urine pregnancy test at Randomization visit are required for female patients of .
  12. In the judgment of the investigator, has any ongoing medical condition that might jeopardize the patient's safety or interfere with the study, including participation in another investigational drug or investigational device study within the 30 days prior to Screening with potential residual effects that might confound the results of this study.
  13. Has any laboratory abnormality or condition that, in the investigator's opinion, could adversely affect the safety of the patient or impair the assessment of study results.
  14. Has any condition that, in the opinion of the investigator, would preclude compliance with the study protocol such as a history of substance abuse, alcoholism or a psychiatric condition.
  15. Has participated in another investigational study within 14 days or 5 half-lives of the prior investigational agent (whichever is longer) prior to screening. Exceptions can be made in the case of observational and/or registry studies upon consultation with the Medical Monitor.
  16. Current treatment with, or chronic use of, a proton pump inhibitor (PPI) or histamine-receptor 2 (H2) antagonist within 14 days or 5 half-lives of the prior agent (whichever is longer) prior to Screening.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
49 participants (actual)

Study arms

  • Active comparator
    AG10 Low Dose

    AG10 400mg tablets twice daily for 28 days

    Drug: AG10

  • Active comparator
    AG10 High Dose

    AG10 800mg tablets twice daily for 28 days

    Drug: AG10

  • Placebo comparator
    Placebo

    Placebo tablets twice daily for 28 days

    Drug: Placebo Oral Tablet

Interventions

  • DrugAG10

    TTR stabilizer

  • DrugPlacebo Oral Tablet

    Nonactive control

06

What researchers measure

Primary outcomes

  1. Change in Diastolic Blood Pressure

    Change in Diastolic Blood Pressure from Baseline to Day 28 (Postdose)

    Time frame: Baseline to Day 28

  2. Change in Heart Rate

    Change in Heart Rate from Baseline to Day 28 (Postdose)

    Time frame: Baseline to Day 28

  3. Change in Respiratory Rate

    Change in Respiratory Rate from Baseline to Day 28 (Postdose)

    Time frame: Baseline to Day 28

  4. Change in Temperature

    Change in Temperature from Baseline to Day 28

    Time frame: Baseline to Day 28

  5. Change in Systolic Blood Pressure

    Change in Systolic Blood Pressure from Baseline to Day 28

    Time frame: Baseline to Day 28

Secondary outcomes

  1. Number of Participants With Threshold Levels of Overall % Stabilization >= 95% and >= 99% by Fluorescent Probe Exclusion (FPE)

    In specialized lab tests on patient samples that measure the stability of the healthy form of TTR, both doses of AG10 were able to reach near complete stabilization.

    Time frame: Day 1 to Day 28

  2. Pharmacokinetic (PK): Steady State Trough Concentration of AG10

    Non-fluctuating minimal amount of AG10 in blood at Day 14 and Day 28

    Time frame: Day 14 and Day 28

07

Results

Posted Nov 16, 2022

Participant flow

Participant flow — Overall Study
MilestoneAG10 400mgAG10 800mgPlacebo
Started161617
Screening161617
Double blind treatment161617
Follow-up161617
Completed161617
Not completed000

Outcome measures

PrimaryChange in Diastolic Blood Pressure

Change in Diastolic Blood Pressure from Baseline to Day 28 (Postdose)

Time frame:
Baseline to Day 28
Reported as:
Mean · mm Hg
Change in Diastolic Blood Pressure
mm HgAG10 400mgAG10 800mgPlacebo
Change in Diastolic Blood Pressure from Baseline to Day 28 (Predose)-3.1 ± 10.06-3.3 ± 11.19-4.3 ± 7.78
Change in Diastolic Blood Pressure from Baseline to Day 28 (Postdose)-2.6 ± 9.660.3 ± 8.54-4.9 ± 9.17
PrimaryChange in Heart Rate

Change in Heart Rate from Baseline to Day 28 (Postdose)

Time frame:
Baseline to Day 28
Reported as:
Mean · beats/minute
Change in Heart Rate
beats/minuteAG10 400mgAG10 800mgPlacebo
Change in heart rate from Baseline to Day 28 (Predose)-2.7 ± 6.88-3.8 ± 6.55-0.4 ± 6.34
Change in heart rate from Baseline to Day 28 (Postdose)-7.3 ± 9.84-4.9 ± 5.84-1.1 ± 8.89
PrimaryChange in Respiratory Rate

Change in Respiratory Rate from Baseline to Day 28 (Postdose)

Time frame:
Baseline to Day 28
Reported as:
Mean · breaths/minute
Change in Respiratory Rate
breaths/minuteAG10 400mgAG10 800mgPlacebo
Change in Respiratory Rate from Baseline to Day 28 (Predose)-0.1 ± 2.23-0.8 ± 3.12-0.4 ± 2.35
Change in Respiratory Rate from Baseline to Day 28 (Postdose)-0.7 ± 1.68-1.1 ± 3.11-1.1 ± 2.93
PrimaryChange in Temperature

Change in Temperature from Baseline to Day 28

Time frame:
Baseline to Day 28
Reported as:
Mean · degrees Celsius
Change in Temperature
degrees CelsiusAG10 400mgAG10 800mgPlacebo
Change in Temperature from Baseline to Day 28 (Predose)0.17 ± 0.7930.06 ± 0.316-0.08 ± 0.506
Change in Temperature from Baseline to Day 28 (Postdose)0.22 ± 0.781-0.02 ± 0.3570.02 ± 0.194
PrimaryChange in Systolic Blood Pressure

Change in Systolic Blood Pressure from Baseline to Day 28

Time frame:
Baseline to Day 28
Reported as:
Mean · mm Hg
Change in Systolic Blood Pressure
mm HgAG10 400mgAG10 800mgPlacebo
Change in Systolic Blood Pressure from Baseline to Day 28 (Predose)-2.7 ± 12.05-8.1 ± 12.36-5.3 ± 13.50
Change in Systolic Blood Pressure from Baseline to Day 28 (Postdose)-2.8 ± 18.41-4.1 ± 8.88-3.4 ± 17.51
SecondaryNumber of Participants With Threshold Levels of Overall % Stabilization >= 95% and >= 99% by Fluorescent Probe Exclusion (FPE)

In specialized lab tests on patient samples that measure the stability of the healthy form of TTR, both doses of AG10 were able to reach near complete stabilization.

Time frame:
Day 1 to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Threshold Levels of Overall % Stabilization >= 95% and >= 99% by Fluorescent Probe Exclusion (FPE)
ParticipantsAG10 400mgAG10 800mgPlacebo
% Stabilization > = 95 %14150
% Stabilization > = 99 %11130
SecondaryPharmacokinetic (PK): Steady State Trough Concentration of AG10

Non-fluctuating minimal amount of AG10 in blood at Day 14 and Day 28

Time frame:
Day 14 and Day 28
Reported as:
Mean · ng/mL
Pharmacokinetic (PK): Steady State Trough Concentration of AG10
ng/mLAG10 400mgAG10 800mg
AG10: PK Plasma Concentration at Day 14 (Pre-Dose)1924.4 ± 837.32257.3 ± 982.81
AG10: PK Plasma Concentration at Day 28 (Pre-Dose)1841.3 ± 483.882439.4 ± 900.08

Adverse events

Collected over Onset date on or after first dose of study drug and not more than 30 days after last dose of study drug, up to day 58.. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AG10 400mg0/16 (0%)1/16 (6.3%)10/16 (62.5%)
AG10 800mg0/16 (0%)0/16 (0%)11/16 (68.8%)
Placebo0/17 (0%)2/17 (11.8%)15/17 (88.2%)
Most frequent serious events
Most frequent serious events
EventAG10 400mgAG10 800mgPlacebo
DyspnoeaRespiratory, thoracic and mediastinal disorders1/160/160/17
Atrial FibrillationCardiac disorders0/160/161/17
Cardiac Failure CongestiveCardiac disorders0/160/161/17
CellulitisInfections and infestations0/160/161/17
Most frequent other events
Showing 10 of 21
Most frequent other events
EventAG10 400mgAG10 800mgPlacebo
ConstipationGastrointestinal disorders1/163/162/17
DiarrhoeaGastrointestinal disorders2/163/160/17
PalpitationsCardiac disorders0/160/163/17
Atrial FibrillationCardiac disorders1/162/160/17
Pain in ExtremityMusculoskeletal and connective tissue disorders0/162/161/17
DizzinessNervous system disorders0/162/160/17
Oedema PeripheralGeneral disorders2/160/160/17
Venous Pressure Jugular IncreasedInvestigations2/160/160/17
Muscle SpasmsMusculoskeletal and connective tissue disorders1/161/162/17
HeadacheNervous system disorders0/161/162/17

Baseline characteristics

Age, Continuous
Age, Continuous(Years)AG10 400mgAG10 800mgPlaceboTotal
Mean73.8 ± 5.6575.4 ± 6.8173.2 ± 7.3574.1 ± 6.58
Sex: Female, Male
Sex: Female, Male(Participants)AG10 400mgAG10 800mgPlaceboTotal
Female2204
Male14141745
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AG10 400mgAG10 800mgPlaceboTotal
Hispanic or Latino1124
Not Hispanic or Latino14141543
Unknown or Not Reported1102
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AG10 400mgAG10 800mgPlaceboTotal
Race (NIH/OMB) — American Indian or Alaska Native0000
Race (NIH/OMB) — Asian1001
Race (NIH/OMB) — Native Hawaiian or Pacific Islander0000
Race (NIH/OMB) — Black or African American43310
Race (NIH/OMB) — White10121335
Race (NIH/OMB) — Other1113
Race (NIH/OMB) — More than one race0000
Race (NIH/OMB) — Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)AG10 400mgAG10 800mgPlaceboTotal
United States16161749
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/meters squared)AG10 400mgAG10 800mgPlaceboTotal
Mean25.42 ± 3.28426.29 ± 3.70527.05 ± 3.60426.27 ± 3.528
Height
Height(Centimeters)AG10 400mgAG10 800mgPlaceboTotal
Mean172.68 ± 7.055175.59 ± 9.738174.52 ± 8.220174.27 ± 8.317
TTR Genotype Status
TTR Genotype Status(Participants)AG10 400mgAG10 800mgPlaceboTotal
Wild Type10111435
Mutant65314
Other0000

1 further baseline measures are reported on the registry.

08

Study locations

13 sites
  • Cedars-Sinai Medical Center
    Beverly Hills, California 90211, United States
  • Stanford University
    Palo Alto, California 94304, United States
  • University of California San Francisco
    San Francisco, California 94143, United States
  • Yale University
    New Haven, Connecticut 06520, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Boston University
    Boston, Massachusetts 02127, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Columbia University
    New York, New York 10032, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29424, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
09

References and documents

Publications

  • Judge DP, Heitner SB, Falk RH, Maurer MS, Shah SJ, Witteles RM, Grogan M, Selby VN, Jacoby D, Hanna M, Nativi-Nicolau J, Patel J, Rao S, Sinha U, Turtle CW, Fox JC. Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol. 2019 Jul 23;74(3):285-295. doi: 10.1016/j.jacc.2019.03.012. Epub 2019 Mar 15. PubMed 30885685 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Oct 2018, 5 months.

Results were first posted in Nov 2022, 4 years 1 month after primary completion. A results delay was requested in Nov 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2018
First posted
Mar 8, 2018
StartActual
Apr 27, 2018
Primary completionActual
Oct 5, 2018
CompletionActual
Oct 5, 2018
Results delay requested
Nov 15, 2019
Results first posted
Nov 16, 2022
Last update
Nov 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03458130
Responsible party
Sponsor
First posted
Mar 8, 2018
Start date
Apr 27, 2018
Primary completion
Oct 5, 2018
Completion
Oct 5, 2018
Results posted
Nov 16, 2022
Last update
Nov 16, 2022

Study contacts

MARK MCGOVERN, RN
study director · Eidos Therapeutics, a BridgeBio company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acoramidis

Start the discussion